Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer – Late-breaking presentation at AACR demonstrates potential to significantly delay onset of drug resistance to EGFR-targeted therapies through combination with a farnesyl transferase inhibitor – –...

Correction: Non-Small Cell Lung Cancer Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade Los Angeles, USA, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Non-Small Cell Lung Cancer Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade  The Non-Small Cell Lung Cancer Pipeline...

Non-Small Cell Lung Cancer Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade Los Angeles, USA, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Non-Small Cell Lung Cancer Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade  The Non-Small Cell Lung Cancer Pipeline...

Non-Small Cell Lung Cancer Therapeutics Market Expected to Reach US$ 15.1 Bn in 2023: Transparency Market Research Albany, NY, Jan. 08, 2016 (GLOBE NEWSWIRE) -- Transparency Market Research has published a new market report titled, “Non Small Cell Lung Cancer Therapeutics Market - Global Industry Analysis,...